Mindray Unveils Latest Strategic Layout; Ping An Launches 'Residential Care Ecosystem' for Home-Based Elderly Care

Mindray Announces Latest Layout

Mindray Releases Latest Strategy, Predicts Uneven Revenue Growth in 2023 but Remains Confident in Achieving Annual Targets

Ping An Insurance (Group) Company Of China, Ltd. Releases "Housing Integration" for Home-Based Elderly Care

On March 30, "Enjoy Longevity, Worry-free Living — China Ping An's Home-based Elderly Care 'Housing Alliance' Launch Conference and Public Welfare Plan Initiation Ceremony" was held in Shenzhen. At the conference, China Ping An, together with its alliance partners, officially launched the home-based elderly care "Housing Alliance" model, introduced the first key service of the 2024 'Three Savings' Service Promotion Year — "573 Home Safety Renovation Service," and jointly launched the "Orange Warm Longevity" public welfare plan with public welfare partners. (Source: Arterial Network)

SPH Officially Releases "2023 Annual Sustainable Development Report and Environmental, Social and Governance Report"

SPH Releases 2023 ESG Report, Emphasizing Sustainable Development, Green Development, and Social Responsibility, Committed to Improving the Health and Quality of Life for the Public, Supporting the Realization of the Chinese Dream. The H5 version of the report is now online, participate in the interaction for a chance to win handicrafts made by patients with rare diseases. (Source: SPH)

Junshi Biosciences: Average Salary of R&D Personnel in 2023 was 535,400 RMB

Junshi Biosciences' R&D Staff Average Salary in 2023 was 535,400 Yuan, First China-Produced PD-1 Monoclonal Antibody Approved by FDA, Breakthrough in International Strategy. Revenue from Toripalimab Increased by 25%, New Indications Added to Medical Insurance Catalog. Meanwhile, the Company Expanded Its Global Commercial Network to Boost Overseas Sales. The Number of R&D Staff Decreased, but the Average Salary Rose by 12.56%. The Company Has Established a Globally Integrated R&D Process. (Source: Arterial Network)

Matwings Technology Completes Pre-A Round Financing Worth Tens of Millions of Yuan

Matwings Technology (hereinafter referred to as "Matwings Technology") has completed a Pre-A round of financing worth tens of millions of yuan. This round of financing was led by金沙江联合资本, with participation from本草资本, 晓池资本, and 四川交研资本. The funds raised will be mainly used to accelerate the industry application of a general large model for protein engineering and to promote industrial upgrading. (Source: Arterial Network)

Anli Xirong Announces Completion of Nearly 100 Million Yuan in Financing to Advance New Drug Development in the Autoimmune Field

On March 28, 2024, Anli Xirong announced that it had successfully completed a nearly 100-million-yuan financing round in recent times. This financing round received strong support from three US dollar funds. The funds will not only support the company in accelerating the research and development process of key projects but also be used to further expand the R&D team to expedite the clinical development of the company's core product pipeline. Additionally, the company will continue to explore cutting-edge innovative technology therapies and seek partners globally to further expand its global influence. (Source: Arterial Network)

New Vaccine Platform Huanuotai Biotech Completes 600 Million Yuan Financing

On March 22, Beijing varnotech Biopharm Ltd. officially announced the completion of a 600 million yuan Series B financing round. This round was jointly led by the Beijing Medical and Health Industry Investment Fund and Ming Tai Fund under Huayin Jintou, with participation from Shuimu Chunjing Capital, Shunxi Fund under Guoguan, Bencao Capital, and Jincheng Fund, among others. Bai Rong Capital served as the exclusive financial advisor for this round. The proceeds will mainly be used to advance the company’s clinical trials for its shingles vaccine and influenza vaccine pipelines, as well as the construction of vaccine production bases and adjuvant production facilities. (Source: Arterial Network)

Zhongbo Ruikang Completes Nearly 100 Million Yuan B Round Financing

Systematic Overall Solution Provider of High-Quality Cell Preparation Intelligent Tool Systems in China——Zhongbo Ruikang (Shanghai) Biotechnology Co., Ltd. ("Zhongbo Ruikang" for short) recently completed a nearly RMB 100 million Series B financing round. This round was led by Daotong Investment, with participation from Qikun Fund and Jinjue Investment. Existing shareholders such as Gaoke Xinjun, Yuanyi Investment, and Innovation Works continued to increase their investments, while Yuanshi Investment and others served as financial advisors for this round. The funds raised will mainly be used for building a modern production system, comprehensively enhancing R&D capabilities, global registration certificate capacity, and rapidly expanding key global markets. (Source: Vbdata)

Multiple R&D Pipelines Continue to "Burn Money," Rongchang Bio Posts a 15 Billion Loss in 2023

Rongchang Bio 2023 Revenue Grows 40.26% to 1.083 Billion Yuan, but Loss Widens to 1.511 Billion Yuan Mainly Due to Increased R&D Pipeline Progress and Commercialization Sales Investment

JOINN Laboratories Releases 2023 Annual Report

High "Monkey Stockpiling" Costs Cause 63% Drop in JOINN Laboratories' 2023 Net Profit, Impacted by Lab Services Profit, Fund Management Returns, and Fluctuations in Biological Asset Values

Six Provinces and Cities Take Action, New Quality Productivity Pushes Medical Industry Potential Track to the Forefront

Six Provincial and Municipal Government Work Reports Propose to Vigorously Develop New Quality Productivity, Including Six Major Directions Such as Future Manufacturing and Information, Aiming to Lead Technological Progress and Drive Industrial Upgrading. Local Governments Have Issued Supporting Policies, and Investment Institutions Are Also Optimistic About Emerging Fields. New Quality Productivity Will Have a Profound Impact on the Medical Industry, Promoting the Iterative Upgrade of Related Enterprises and Industries. Some Local Governments Have Formulated Specific Policies to Support Innovative Enterprise Development. (Source: Arterial Network)